Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails
Executive Summary
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.
You may also be interested in...
Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
Merck Ups Marketing Spend For Januvia And Gardasil As Competitors Stumble
Merck's decision to step up marketing spend for two of its new products, the DPP-4 inhibitor Januvia for diabetes and the human papilloma virus vaccine Gardasil,may reflect an effort to take advantage of delays in the launches of potential competitor products
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: